Investigating Tumour Biology Using Regulated RNAi In Cells And Mice
Funder
National Health and Medical Research Council
Funding Amount
$305,915.00
Summary
Inhibiting gene expression using the recently discovered process known as RNA interference (RNAi) can be used as an experimental tool to analyse specific genes, in cells and genetically engineered animal models of human disease. I propose to use RNAi to mimic human cancer gene mutations in mouse cancer models, and aim to discover novel tumour suppressor genes. A further aim is to validate potential drug targets in cancer by using RNAi to inhibit specific genes in established mouse tumours.
Decoding The Transcriptional Program Of Vessel Growth In Health And Disease
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
Lymphatic vessels are essential to maintain fluid balance in most tissues of the human body. Further the lymphatic vasculature plays a central role during cancer and contributes to tumour metastasis. Despite this integral function in health and disease little is known about the molecular programs that coordinate gene expression to build a functional vasculature. This research project will address this gap in our knowledge and will open up new therapeutic avenues for lymphatic vascular disorders
Wounds, burns and scalds are frequent injuries which can lead to deformity, disfigurement and loss of movement. We have shown that the cytoskeletal protein, Flightless I (FliI), is an important regulator of wound repair. We plan to further investigate FliI in wound and burn injuries using new cell-specific transgenic animal models and to develop a new FliI-antibody based therapy to treat wound and burn injuries.
Novel Pathomechanisms And Therapeutic Targets In Neurodegenerative Diseases
Funder
National Health and Medical Research Council
Funding Amount
$340,038.00
Summary
This fellowship will provide new insight into the molecular processes underlying onset and progression of common brain conditions, including Alzheimer’s disease, frontotemporal dementia and motor neuron disease. Furthermore, new therapeutic targets for these diseases will be developed and tested in model systems, to facilitate future translation into clinical application, and to overcome the lack of treatments.